News
CADTH is pleased to announce the appointment of Mr. David Agnew to Chair of the CADTH Board of Directors, effective July 10, 2018.
Mr. Agnew has led a distinguished career as an executive and senior leader in the public, private, and non-profit sectors. He is currently the President of Seneca College, one of the largest colleges in Canada. His d...
CADTH is pleased to announce the launch of its new Pharmaceutical Reviews Update newsletter.
The Pharmaceutical Reviews Update consolidates our CDR Update, pCODR Update, Therapeutic Review Update, and Updates for Patient Groups into a single newsletter. It will make it easier for you to stay on top of changes to our review processes, and redu...
Project
Call for Feedback
Feedback Due By
Availability and Access to Non-Pharmacological Treatment of Chronic Non-Cancer Pain in Canada
2018-07-04
2018-07-18
Consultation Document
Product Type
Submit Stakeholder Feedback
Draft Report
Environmental Scans
Submit
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.
Jublia
Brand name
Generic name
Manufacturer
In...
Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing pharmaceutical landscape
